LISAvienna: April 2024 newsletter available for reading online

Name: _pk_id Used for : Is used to store an unique ID for each user Duration : 13 Months
Name: &nbsp;_pk_ses, _pk_cvar, _pkhsr Used for :&nbsp;Session cookies that store temporary data Duration :&nbsp;30 minutes
Name: mtm_consent Used for : Stores cookie preferences Duration : 30 years

We’re pleased to share a selection of life sciences news from Vienna with you again. Among others, we put headlines from these organizations center stage Boehringer Ingelheim, QMD Services, IMBA, Hookipa Pharma, Octapharma, MedUni Vienna, CeMM, Evercyte, TAmiRNA, ViruSure, Vetmeduni Vienna, Uni Vienna, G.ST Antivirals, ImageBiopsy Lab, XUND, RetInsight, BBMRI.at and LBG.

In addition, we update you on events in Vienna, abroad and online as well as on funding opportunities and on recently published reports we recommend for reading. Please also find a link to our most recent article on VIENNA2030 included. It focuses on how the Vienna Business Agency has been opening doors to research, technology and innovation for the next generation. A special highlight are short clips from DMEA with Life Science Austria, nyra health and XUND, information ViennaUP and on The MedTech Forum.

Access the newsletter in your browser: https://mailchi.mp/lisavienna/newsletter-april-30-2024
Register here: https://www.lisavienna.at/newsletter/

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.

LISAvienna: April 2024 newsletter available for reading online

UpNano: Novel Process for 3D-printing macro-sized fused silica parts with hi-res features

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

MedUni Vienna: Kidney transplantation: Combined cell therapy reduces donor-specific immune response